About Pyxis Oncology, Inc.
https://www.pyxisoncology.comPyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers.
CEO
Lara S. Sullivan MBA
Compensation Summary
(Year 2024)
Salary $625,000
Stock Awards $1,249,152
Option Awards $4,766,566
Incentive Plan Pay $421,875
All Other Compensation $10,350
Total Compensation $7,072,943
Industry Biotechnology
Sector Healthcare
Went public October 8, 2021
Method of going public IPO
Full time employees 44
ETFs Holding This Stock
Summary
Total 23
Showing Top 3 of 23
Ratings Snapshot
Rating : C+
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 2
Price To Earnings 1
Price To Book 3
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 2
Outperform 1
Overweight 1
Showing Top 4 of 4
Price Target
Target High $8
Target Low $5
Target Median $7
Target Consensus $6.67
Institutional Ownership
PFIZER INC
Shares:7.03M
Value:$14M
LAURION CAPITAL MANAGEMENT LP
Shares:3.63M
Value:$7.22M
BLACKROCK INC.
Shares:2.79M
Value:$5.54M
Summary
% Of Shares Owned 44.14%
Total Number Of Holders 83
Showing Top 3 of 83
Market Cap $90.26 M
52w High $5.55
52w Low $0.83
P/E -1.26
Volume 754.99K
Outstanding Shares 62.25M
About Pyxis Oncology, Inc.
https://www.pyxisoncology.comPyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 ▼ | $23.46M ▲ | $-22M ▼ | 0% ▲ | $-0.35 ▼ | $-21.47M ▼ |
| Q2-2025 | $2.82M ▲ | $22.57M ▼ | $-18.35M ▲ | -650.85% ▼ | $-0.3 ▲ | $-19.21M ▲ |
| Q1-2025 | $0 | $22.91M ▼ | $-21.16M ▲ | 0% | $-0.35 ▲ | $-22.36M ▼ |
| Q4-2024 | $0 | $40.07M ▲ | $-35.57M ▼ | 0% | $-0.58 ▼ | $-18.55M ▲ |
| Q3-2024 | $0 | $23.75M | $-21.2M | 0% | $-0.35 | $-23.02M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $77.73M ▼ | $105.6M ▼ | $36.83M ▲ | $68.78M ▼ |
| Q2-2025 | $88.94M ▼ | $123.22M ▼ | $35.57M ▲ | $87.64M ▼ |
| Q1-2025 | $105.43M ▼ | $135.87M ▼ | $32.76M ▼ | $103.1M ▼ |
| Q4-2024 | $126.93M ▼ | $157.18M ▼ | $36.43M ▼ | $120.75M ▼ |
| Q3-2024 | $144.82M | $195.31M | $41.63M | $153.68M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-22M ▼ | $-13.28M ▲ | $11.47M ▼ | $-8K ▲ | $-1.81M ▲ | $-13.29M ▲ |
| Q2-2025 | $-18.35M ▲ | $-17.26M ▲ | $15.3M ▼ | $-67K ▼ | $-2.03M ▲ | $-17.26M ▲ |
| Q1-2025 | $-21.16M ▲ | $-22.54M ▼ | $15.82M ▼ | $0 ▼ | $-6.71M ▼ | $-22.54M ▼ |
| Q4-2024 | $-35.57M ▼ | $-19.29M ▼ | $26.66M ▲ | $50K ▼ | $7.42M ▲ | $-19.29M ▼ |
| Q3-2024 | $-21.2M | $-14.66M | $-8K | $1.66M | $-13.02M | $-14.66M |
CEO
Lara S. Sullivan MBA
Compensation Summary
(Year 2024)
Salary $625,000
Stock Awards $1,249,152
Option Awards $4,766,566
Incentive Plan Pay $421,875
All Other Compensation $10,350
Total Compensation $7,072,943
Industry Biotechnology
Sector Healthcare
Went public October 8, 2021
Method of going public IPO
Full time employees 44
ETFs Holding This Stock
Summary
Total 23
Showing Top 3 of 23
Ratings Snapshot
Rating : C+
Discounted Cash Flow 5
Return On Equity 1
Return On Assets 1
Debt To Equity 2
Price To Earnings 1
Price To Book 3
Overall Score 2
Most Recent Analyst Grades
Grade Summary
Buy 2
Outperform 1
Overweight 1
Showing Top 4 of 4
Price Target
Target High $8
Target Low $5
Target Median $7
Target Consensus $6.67
Institutional Ownership
PFIZER INC
Shares:7.03M
Value:$14M
LAURION CAPITAL MANAGEMENT LP
Shares:3.63M
Value:$7.22M
BLACKROCK INC.
Shares:2.79M
Value:$5.54M
Summary
% Of Shares Owned 44.14%
Total Number Of Holders 83
Showing Top 3 of 83